Existing data sources for clinical epidemiology: The clinical laboratory information system (LABKA) research database at Aarhus University, Denmark by Grann, Anne Fia et al.
© 2011 Grann et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Epidemiology 2011:3 133–138
Clinical Epidemiology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
133
METHODOLOGY
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CLEP.S17901
Existing data sources for clinical epidemiology:  
The clinical laboratory information system (LABKA) 
research database at Aarhus University, Denmark
Anne Fia Grann
Rune Erichsen
Anders Gunnar Nielsen
Trine Frøslev
Reimar W Thomsen
Department of Clinical Epidemiology, 
Aarhus University Hospital,  
Aarhus, Denmark
Correspondence: Anne Fia Grann 
Department of Clinical Epidemiology, 
Institute of Clinical Medicine, Aarhus 
University Hospital, Olof Palmes Allé 
43-45, DK-8200 Aarhus N, Denmark 
Tel +45 8942 4800 
Fax +45 8942 4801 
Email afg@dce.au.dk
Abstract: This paper provides an introduction to the clinical laboratory information system 
(LABKA) research database in Northern and Central Denmark. The database contains millions 
of stored laboratory test results for patients living in the two Danish regions, encompassing 
1.8 million residents, or one-third of the country’s population. More than 1700 different types 
of blood test analyses are available. Therefore, the LABKA research database represents an 
incredible source for studies involving blood test analyses. By record linkage of different 
Danish registries with the LABKA research database, it is possible to examine a large number 
of biomarkers as predictors of disease risk and prognosis and as markers of disease severity, 
and to evaluate medical treatments regarding effectiveness and possible side effects. Large 
epidemiological studies using routinely stored blood test results for individual patients can be 
performed because it is possible to link the laboratory data to high-quality individual clinical 
patient data in Denmark.
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Introduction
Every day, millions of blood specimens are analyzed as part of routine clinical work in 
hospitals and medical practices throughout the world. Laboratory tests performed are 
analyzed in clinical laboratories and are usually recorded in computer-based labora-
tory information systems.1
The clinical laboratory information system (LABKA) research database in   Denmark 
contains millions of stored laboratory test results from Danish patients living in the 
North Denmark region and Central Denmark region, representing one-third of the 
country’s population. Therefore, the LABKA research database represents an incred-
ible source for studies involving blood test analyses. Large epidemiological studies 
can be performed, if the laboratory data can be linked to high-quality clinical patient 
data at the individual level, as is the case in Denmark.
Danish health care, disease, and population registries are recognized as being 
amongst the best in the world, in particular because of their large size, long recording 
periods, high quality, and completeness.2,3 Widespread health registration in Denmark 
is based on the Danish National Health Service, which is coordinated through five 
administrative regions. This health system provides what is essentially a monopoly 
service of tax-funded medical care for all 5.5 million Danish residents. Since 1968, all 
Danish residents have been assigned a unique personal identifier, ie, the civil personal 
registration (CPR) number, which is used in all health and population databases and Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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facilitates unambiguous computerized record linkage. In this 
paper, we present an overview of the clinical laboratory 
information system and the LABKA research database. Our 
objective is that researchers understand the Danish labora-
tory information system and learn some of the potential 
uses that can be made of the Danish biochemistry data in 
clinical research.
Danish clinical laboratory  
information systems
Today, computer-based laboratory information systems 
are functioning as a central routine diagnostic tool for 
medical doctors in all private clinics and hospital depart-
ments in   Denmark. New laboratory test results are entered 
immediately and directly into the system, with automatic 
online updating and access to results for all relevant hospital 
  personnel. In 1979, the first version of a real-time computer-
based laboratory information system, ie, LABKA, was 
designed and implemented at Rigshospitalet in Copenhagen, 
initially for internal use in the clinical chemistry department 
only.4 Since then, the development of the LABKA system 
has continued.
In 1985, LABKA was implemented as part of the daily 
routine in all clinical departments at the Aarhus Amtssygehus 
(Central Denmark region) as the first commercial laboratory 
information system. Gradually, LABKA expanded and today 
the most recent system, called LABKA II,5 is implemented in 
all clinical chemistry departments in public hospitals (more 
than 40) in three of the five Danish administrative regions, 
ie, the North Denmark region, the Central Denmark region, 
and the Copenhagen region (data from the latter region is not 
included in the LABKA research database, see below). The 
LABKA system was developed by the Dansk Datalab, later 
renamed the CSC-Datalab.5
The LABKA system holds test results from every blood 
sample taken in any public or private hospital or by any 
general practitioner and submitted to any clinical chemistry 
department located in the three Danish regions.   Exceptions 
are some results from small and rapid point-of-care devices 
used by medical staff or patients themselves for instant 
analysis of, eg, INR, blood glucose, hemoglobin, and 
C-reactive protein (CRP).6,7 When a blood sample has been 
analyzed in the clinical chemistry department laboratory, 
the sample is destroyed and the results are electronically 
transmitted to the requesting hospital department or general 
practitioner through the LABKA system. The information 
is recorded in a uniform way according to the international 
NPU (Nomenclature, Properties and Units) coding system. 
The NPU code is the unique identification number for each 
single   investigation. The NPU coding system provides a 
terminology for identification of clinical laboratory test 
values following the international recommendations for 
efficient electronic communication in clinical laboratories, 
and ensures that names and units are shown in a uniform 
manner.8
LABKA research database
The laboratory information systems provide data for the 
LABKA research database. Traditionally, it has been called 
“the LABKA database” after the commercial name of the 
laboratory information system. A more correct name might 
have been the “laboratory information system database”. 
The population covered by the database comes from a well-
defined geographical area corresponding to two of the five 
Danish administrative regions, ie, the North Denmark region 
and the Central Denmark region, encompassing 1.8 million 
residents. The regions consist of mixed rural and urban areas 
with modestly growing populations.
Hospitals started transferring data to the LABKA 
database in different time periods, beginning in 1990. The 
database is considered to have full geographical coverage 
in the North Denmark region since 1997 and in the Central 
Denmark region since 2000. The LABKA research database 
is currently updated once a year, and is managed by the 
Department of Clinical Epidemiology at Aarhus University 
Hospital.
Information recorded in the  
LABKA database
As previously indicated, all results of analyzed blood samples 
drawn from patients from hospital departments and medi-
cal practices in the North and Central Denmark regions are 
recorded in the LABKA research database according to NPU 
codes and specific analysis numbers. In addition, date of 
blood sample analysis, patient CPR number, and identifica-
tion code for the physician or hospital department requesting 
the blood test analysis are recorded.
Table 1 shows the number of tests recorded in the 
LABKA research database for some of the most common 
analyses used in everyday clinical practice.
 Around 1700 different blood sample analyses are 
available in the database. Among these are 76 pharmaco-
logical analyses. Table 2 shows selected examples from the 
LABKA database of a number of pharmacological analyses 
where monitoring is recommended as a guide to treatment. 
Analyzed blood samples are by far the most common type Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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of analysis in the LABKA research database. However, 
other specimen analysis types such as urine and fecal occult 
blood tests, and cerebrospinal fluid are also accessible in 
the database.
Data quality
When evaluating the overall quality of the laboratory data 
in the LABKA research database, it is important to consider 
whether all laboratory data are recorded and whether the 
information recorded in the registry is correct. Information in 
the LABKA research database is obtained directly, electroni-
cally, and without filtering from the LABKA systems in the 
North Denmark region and the Central Denmark region, theo-
retically with minimal risk of data loss. Because the LABKA 
systems in the two regions function as an indispensable daily 
routine diagnostic tool for all medical personnel, and is based 
on immediate direct entry of approved results into the system, 
the proportion of missing data in the LABKA system (and 
in turn in the LABKA research database) is extremely low. 
Errors due to technical faults are hard to detect, but are the 
same errors that may be seen in everyday clinical practice. 
Unsuccessful and cancelled blood samples are also recorded 
in the database, and therefore can be excluded before using 
LABKA data in research. Furthermore, in the different hos-
pital laboratories, different medical equipment may have 
been used over time, and variation in, eg, units and normal 
ranges may therefore occur for some analyses. Finally, 
different local analysis codifications have been used for a 
Table 1 NPU codes and numbers of analyzed blood tests from January 1, 1999 to December 31, 2007, showing some of the most 
frequent blood test analyses in the LABKA database
Blood test NPU code 1999–2001 2002–2004 2005–2007 Total blood tests Patients in total*
Sodium 03429 2,139,244 2,708,127  3,352,908  8,200,279 938,173
Potassium 03230 2,202,088 2,838,745  3,462,178  8,503,011 950,680
Creatinine 01807  2,273,490 2,867,271 3,104,634 8,245,395 899,050
18016
18105
Urea 01459 1,103,001 1,190,903  1,183,272  3,477,176 490,401
Albumin 01132 1,309,050 1,674,173 2,237,524 5,220,747 771,107
19673
Glucose 02187
02192
02193
02195
04093
08520
08567
08869
08916
08972
22069-
22089
22095
22099-
22126
1,276,282 1,470,945 1,707,899  4,455,126 590,015
Glycosylated 
hemoglobin
02307
03835
27300
277,898 415,222  582,800 1,275,920 298,777
Hemoglobin 02319
02322
2,209,214 2,735,613  3,288,734  8,233,561 1,011,861
Leukocytes 02593
02596
04100
18156
2,324,157 3,065,182 3,217,612 8,606,951 951,268
C-reactive 
protein
01423
05027
19748
1,277,912 1,686,060  1,775,578  4,739,550 781,110
Total – 16,392,336 20,652,241 23,913,139 60,957,716
Notes: *The numbers are computed as the sum of all blood tests in each period. In this table, a person can have one or more blood test results in each period. 
Abbreviation: NPU, Nomenclature, Properties and Units.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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number of tests in the early years of the database before the 
uniform NPU coding was implemented in the laboratories 
in 2001. Many of these previous analysis codes have been 
transformed into NPU codes, but this transformation is not 
fully complete for all laboratory tests. However, correct 
transformation of different codes and units as needed by the 
researcher is possible with the information available in the 
LABKA research database.
Data linkage possibilities
All patients are registered by their individual CPR number, 
and this is one of the database’s major strengths. Use of the 
CPR number, assigned to all Danes, makes it possible to 
link laboratory data to a wide range of other medical and 
socioeconomic Danish registries. This includes the Danish 
national registry of patients (with data on all hospital admis-
sions and discharge diagnoses since 1977 and all outpatient 
visits since 1995),9 the Danish civil registration system 
(which contains exact dates of immigration, emigration, 
and death, if any), and the prescription database at Aarhus 
University.10 Hereby, it is possible to build large cohorts with 
detailed longitudinal data that include full hospitalization 
history and outpatient visits, comorbidity data, prescriptions 
redeemed at any pharmacy, and detailed cumulated labora-
tory results. The population base makes the database well 
suited for matched cohort and case-control studies, with the 
Danish civil registration system facilitating the selection of 
controls from the underlying population using incidence 
density sampling.11
Examples of studies involving linkage between the 
LABKA database and other data sources are given below. 
Even unlinked data from the LABKA database can provide 
a wealth of information, but linking data with, eg, the Danish 
national registry of patients, may provide researchers with 
invaluable data on the course of acute as well as chronic 
diseases.
For a number of drugs, monitoring of therapeutic ranges 
is recommended as a guide to treatment, eg, antipsychotic, 
antibiotic, antiepileptic, or immunosuppressive treatment 
securing optimal drug effect, minimal side effects, compli-
ance, and dosage of medical treatments. Pharmacological 
analyses are also used when diagnosing drug poisoning.
The prescription database at Aarhus University collects 
data on reimbursed medications dispensed by all commu-
nity pharmacies in the North Denmark region and Central 
Denmark region, ie, the same regions as in the LABKA 
database. Combining pharmacy records with laboratory 
data can generate important studies in clinical epidemiol-
ogy, including drug utilization studies, safety monitoring, 
and etiologic research. LABKA data can provide up-to-
date information on treatment status, and thereby evaluate 
medical therapies in both hospitals and in primary care. It 
is desirable to develop methods that reflect current clinical 
practice in large geographical areas and to be able to study 
Table 2 Examples of a number of pharmacological analyses where monitoring is indicated as a guide to treatment
Blood test NPU code 1999–2001 2002–2004 2005–2007 Total blood tests Patients in total*
Clozapine 04114 3660 5535 20,004 29,199 10,437
Lamotrigine 08732 8607 13,075 17,143 38,825 8075
Valproate 03735
14378
12,147 12,904 13,577 38,628 7018
Nortriptyline 02923 3385 4954 4925 13,264 3817
Lithium 02613 20,318 20,867 20,420 61,605 4189
Paracetamol 03024
16789
18232
4005 6002 5584 15,591 9290
Salicylate 03383 3290 4339 4258 11,887 6587
Gentamicin 02164
19779
2164 6609 8645 17,418 6581
Vancomycin 19929 203 1090 2552 3845 529
Methotrexate 02739 3244 3287 3556 10,087 736
Cyclosporine 01592
03990
19725
19726
17,116 14,938 16,532 48,586 2995
Digoxin 01886 43,914 32,255 29,061 105,230 26,920
INR 01685 720,035 922,822 983,899 2,626,756 300,527
Total – 842,088 1,048,677 1,130,156 3,020,921
Notes: *The numbers are computed as the sum of all blood tests in each period. In this table, a person can have one or more blood test results in each period.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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the treatment status for different kinds of drugs, by use of 
information from the LABKA research database and other 
existing registries.
Examples of studies using  
LABKA data
Biomarkers from the LABKA database may be investigated 
as prognostic predictors. In a recent cohort study, we 
linked patients with bacteremia identified in the North 
Denmark bacteremia research database for the 1997–2004 
period12 with the LABKA database to examine the 
association between the CRP level at the time of blood 
culture draw and subsequent bacteremia mortality. We 
were able to identify CRP measurements, including exact 
date, hour, and minute of drawing the CRP specimen, for 
5449 (95.1%) of 5730 bacteremia patients.13 Thirty-day 
mortality increased consistently from 13.2% in the first 
CRP quartile (10–64 mg/L) to 24.8% in the fourth CRP 
quartile (241–688 mg/L). After controlling for confounding 
factors, the baseline CRP level remained an indepen-
dent predictor for 30-day mortality. The adjusted 30-day 
mortality rate ratios for patients in the second, third, and 
fourth CRP quartiles were 1.38 (95% confidence interval 
[CI] 1.13–1.69), 1.70 (95% CI 1.40–2.06), and 2.38 (95% 
CI 1.96–2.87), respectively.13
Biomarkers from the LABKA database may also be 
investigated as treatment outcomes. A study from 2007 
examined the association between aminoglycoside therapy 
and increase in serum creatinine among patients with 
  bacteremia.14 Serum creatinine was available at baseline for 
77.9% of patients treated with aminoglycosides and 79.2% 
of patients not treated with aminoglycosides. An increase in 
serum creatinine of $45 mmol/L within 14 days after the 
bacteremia was observed almost as often in aminoglycoside-
treated and non-aminoglycoside-treated patients (14.1% 
versus 12.4%, adjusted odds ratio 1.06; 95% CI 0.63–1.79). 
We could prove that this finding was partly due to amino-
glycosides being less frequently used in patients with high 
baseline creatinine levels (who had the highest risk of further 
increases in creatinine).14
Biomarkers from the LABKA database may further be 
investigated as markers of underlying disease. Kornum et al 
conducted a large case-control study to examine whether 
diabetes and glycemic control assessed by HbA1c level is 
a risk factor for hospitalization with pneumonia.15 Their 
34,239 pneumonia patients and 342,390 population controls 
were linked to the LABKA database. One or more HbA1c 
measurements within 12 months were available for 2731 
(61%) of pneumonia patients with diabetes and for 16,605 
(58%) of control subjects with diabetes. The most recent 
HbA1c   measurement was used in the analysis. Compared 
with subjects without diabetes, the adjusted relative risk for 
pneumonia was 1.22 (95% CI 1.14–1.30) for diabetic subjects 
whose HbA1c level was ,7% and 1.60 (95% CI 1.44–1.76) 
for diabetic subjects whose HbA1c level was $9%. The 
authors earlier demonstrated that inflammatory markers 
(including CRP and leukocytes) on admission with pneu-
monia were similarly high in diabetic and other individuals, 
suggesting that there was no major hospital referral bias 
associated with having diabetes.16
Accessing the LABKA data
Data files are kept for research purposes by the Department 
of Clinical Epidemiology, while the original data files are 
kept by the North Denmark region and Central Denmark 
region. The Danish Act on Processing of Personal Data 
(Persondataloven) provides the legal basis for the abil-
ity of public institutions, including universities, to retain 
person-identifiable health data for research purposes. In 
order to access the data from the LABKA research database, 
researchers are welcome to contact Hanne K Schlosser 
hks@dce.au.dk at the Department of Clinical Epidemiol-
ogy, Aarhus University Hospital (www.kea.au.dk). There 
is a steering committee for the database. Furthermore, use 
of any health data requires project-specific permission 
from the Data Protection Agency (Datatilsynet, www.
datatilsynet.dk).
Conclusion
The LABKA research database in Denmark contains many 
millions of stored laboratory test results covering 1.8 million 
people for a period of more than 10 years. These data may 
facilitate research within all areas of medicine. By record 
linkage with other Danish databases and registries, it is 
possible to conduct large clinical epidemiologic studies to 
examine important biomarkers as predictors of disease risk 
and prognosis, and to evaluate medical treatments regarding 
efficacy and possible side effects.
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